CD160 and melanoma: Baitsch et al. reported that in patients with malignant melanoma, tumor-infiltrating CD8+ T cells express many inhibitory molecules, such as BTLA, TIM-3, LAG-3, KRLG-1, 2B4, CD160, PD-1, and CTLA-4 [41].